Pegasys
peginterferon alfa-2a
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Pegasys. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Pegasys.
For practical information about using Pegasys, patients should read the package leaflet or contact their doctor or pharmacist.
Authorisation details
Product details | |
---|---|
Name |
Pegasys
|
Agency product number |
EMEA/H/C/000395
|
Active substance |
peginterferon alfa-2a
|
International non-proprietary name (INN) or common name |
peginterferon alfa-2a
|
Therapeutic area (MeSH) |
|
Anatomical therapeutic chemical (ATC) code |
L03AB11
|
Publication details | |
---|---|
Marketing-authorisation holder |
zr pharma& GmbH
|
Revision |
45
|
Date of issue of marketing authorisation valid throughout the European Union |
20/06/2002
|
Contact address |
Hietzinger Hauptstrasse 37 |
Product information
29/09/2022 Pegasys - EMEA/H/C/000395 - II/0112
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Immunostimulants
Therapeutic indication
Chronic hepatitis B
Adult patients
Pegasys is indicated for the treatment of hepatitis B envelope antigen (HBeAg)-positive or HBeAg-negative chronic hepatitis B (CHB) in adult patients with compensated liver disease and evidence of viral replication, increased alanine aminotransferase (ALT) and histologically verified liver inflammation and/or fibrosis (see sections 4.4 and 5.1).
Paediatric patients 3 years of age and older
Pegasys is indicated for the treatment of HBeAg-positive CHB in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum ALT levels. With respect to the decision to initiate treatment in paediatric patients see sections 4.2, 4.4 and 5.1.
Chronic hepatitis C
Adult patients
Pegasys is indicated in combination with other medicinal products, for the treatment of chronic hepatitis C (CHC) in patients with compensated liver disease (see sections 4.2, 4.4 and 5.1).
For hepatitis C virus (HCV) genotype specific activity, see sections 4.2 and 5.1.
Paediatric patients 5 years of age and older
Pegasys in combination with ribavirin is indicated for the treatment of CHC in treatment-naïve children and adolescents 5 years of age and older who are positive for serum HCV-RNA.
When deciding to initiate treatment in childhood, it is important to consider growth inhibition induced by combination therapy. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case by case basis (see section 4.4).
Assessment history
News
-
13/10/2017
-
21/03/2014
-
19/11/2013
-
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 January 201318/01/2013
-
23/10/2012
-
20/07/2012